


# Oxford-Yale expedition to Pike's Peak, Colorado

J. S. Haldane and colleagues - July 1911



# Signalling hypoxia in cells

$O_2$





Sensor




Epo

Krogh

J. Physiol 1919 52 409-415



Co-ordination of blood vessel growth and cellular metabolism  
Hoppeler and Kayar 1991



# Signalling hypoxia in cells

O<sub>2</sub>





Sensor



Epo

Transgenic marker gene strategy indicates that erythropoietin producing cells are **Interstitial fibroblasts**

Cobalt poisoning causes erythrocytosis without obvious metabolic compromise



# Dissection of hypoxia signalling pathways

Transcription factors


**ERYTHROPOIETIN**

Angiogenesis

Vasomotor regulators

Matrix metabolism

Transporters



Iron metabolism

Ion Channels

Redox control

Glucose metabolism

Growth factors

Mitochondrial control


**PHOSPHOGLYCERATE  
KINASE**

Oncogenes


Fat metabolism

Apoptotic regulators

## Regulation of HIF by oxygen



# The von Hippel-lindau tumour suppressor is directly linked to hypoxia pathways





Certain types of kidney cancer are associated with

Excessive red cell production (erythropoietin)


Excessive blood vessel growth (angiogenesis)

These cancer are defective for the VHL tumour suppressor (VHL)




# Signalling modification is prolyl hydroxylation

Biochemical analysis  
~~Heat labile extract~~  
~~Non-enzymatic oxidation~~  
~~NADH/NADHoxidase~~  
 Oxygen  
 Iron  
~~ATP~~




HIF prolyl hydroxylation implies a mechanism of oxygen sensing






HIF prolyl hydroxylases - a set of Fe(II) and 2-oxoglutarate dioxygenases that are conserved throughout the animal kingdom




# Implications of Darwinian evolution for understanding (and translating) biology

## Basic helix-loop-helix proteins




(eukaryotes; yeast, plants,  
animals)

## PAS domain proteins




(sensing functions, many phyla;  
incl. prokaryotes, eukaryotes)

## PHD – like enzymes



(range of non-metazoan as well  
as non-metazoan species)

## FIH – like enzymes



(range of species incl.  
prokaryotes and eukaryotes)


bHLH – PAS – \* ODD – \* CAD  
**Hypoxia inducible factor (HIF)**  
(basic-helix-loop-helix PAS proteins)

# Therapeutic potential of activating HIF pathways by inhibition of HIF hydroxylases

**Erythropoiesis** -Epo, Iron metabolism

**Angiogenesis** –Growth factors, Receptors, Matrix

**Cytoprotection** –Energy metabolism, Anti-oxidants



**Wound healing** – Inflammation, oxygen delivery

**Stem cell behaviour** – Transcription factors

**Adiposity** –Lipid metabolism, adipose differentiation

**Glucose homeostasis** – Energy metabolism


**Respiratory stimulant** – Channels glomus cells

# Co-evolution of HIF hydroxylase pathways and animals

Trichoplax chromosome:

Scaffold 5 — taPHD

taHIFα




Would it be possible to design more selective small molecule interventions on the PHD/HIF system?

Mammalian HIF has two hydroxylation sites NODD (N-terminal) and CODD (C-terminal)  
evidence for selective hydroxylase activity from human genetics



A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis

Melanie J. Percy<sup>1</sup>, Quan Zhao<sup>1</sup>, Adrian Flores<sup>1</sup>, Claire Harrison<sup>1</sup>, Terence R. J. Lippin<sup>1</sup>, Patrick H. Maxwell<sup>1</sup>, Mary Frances McMullin<sup>2</sup>, and Frank S. Lee<sup>1\*</sup>\*\*




- Re-introduction of wild type and mutant human PHD2 into MEFs that are null for all 3PHDs
- Assay HIF status by hydroxy-amino acid specific antibodies – block of degradation with MG132


Would it be possible to design more selective small molecule interventions on the PHD/HIF system?



IOX4



IOX2



BNS

Multiple HIF/PHD isoforms co-evolved  
with specialist oxygen delivery  
systems in animal evolution

Relative isoform specificity of small  
molecule inhibitors of PHD/HIF  
hydroxylation should be possible


Would this be useful?

# Altitude physiology and the concept of oxygen sensing

J.S. Haldane and colleagues , Pike's Peak 1911



Haldane, Fitzgerald, Schneider, Henderson and Douglas at top of Pike's peak, 1911



## Acute acclimatization



pre-exposure to hypoxia (days)

↑ pre-increased sensitivity  
to acute hypoxia  
(minutes)






Are specific components of the hypoxia response linked to specific components of the HIF/PHD system?

Ventilatory sensitivity to acute hypoxia pre- and post- 7 days at 10% oxygen (ca. 5000m)




## Enhanced hypoxic ventilatory response in Phd2<sup>+/-</sup> mice (10% O<sub>2</sub> + 3% CO<sub>2</sub>)



Time (min)

# Ventilation acclimatization and erythropoietic responses to simulated altitude are largely driven by the HIF-2 $\alpha$ isoform




Conditional inactivation  
of HIF- $\alpha$  by Rosa 26  
driven CreER

Animals studied 10 days  
after first dose of  
tamoxifen

Sensitizing exposure  
10% O<sub>2</sub> (up to 7 days)


Acute exposure  
10% O<sub>2</sub> + 3 CO<sub>2</sub> (5  
min)




# Ventilation acclimatization to simulated altitude is largely driven by HIF-2 $\alpha$

Inducible inactivation of HIF-1 $\alpha$  or HIF-2 $\alpha$  in adult life


Proliferation of cells in the carotid body after 7 days exposure to 10% oxygen – BrDU labelling




*Hif-1 $\alpha$ <sup>fl</sup>*





*Hif-1 $\alpha$ <sup>fl</sup>; CreER*



*Hif-2 $\alpha$ <sup>fl</sup>*





*Hif-2 $\alpha$ <sup>fl</sup>; CreER*





# Pan-genomic analysis of binding of HIF binding

Comparison of HIF-1 $\alpha$  and HIF-2 $\alpha$  binding by ChIP-seq (MCF7 breast cancer cells)



# Pan-genomic analyses reveal differences in the transcriptional architecture of HIF-1 $\alpha$ binding versus HIF-2 $\alpha$ binding

HIF-1 $\alpha$  binding sites cluster much more strongly at promoters than HIF-2 $\alpha$  binding sites




Marked isoform selective activity of chromatin bound HIF- $\alpha$  is strongly distant dependent

Near complete preferential action of HIF-2 on genes lying at a distance from DNA binding site

Genes lying close (<2Kb) to their HIF binding site


Genes lying distant (>10Kb) from their HIF binding site



# Very incomplete separation of HIF-1 vs HIF-2 function by gene ontology programs

HIF-1

Metabolic,  
cytostatic  
responses  
(less  
oxygen  
demand) ?



HIF-2

Reparative  
responses  
(more  
oxygen  
supply)



## Evolution of distinct characteristics of the HIF response

HIF-1 (early invertebrate form) versus HIF-2 (more modern vertebrate form)

Differences in transcriptional biochemistry  
- produced by agnostic variation

- HIF-1 dominant action at promoters – widely expressed genes)
- HIF-2 enhancer action; dominant action on RNA regulatory networks – more cell-type specific genes

A fundamental design flaw for rationale drug development

Differences in physiological function  
- produced by Darwinian selection

- HIF-1 generally expressed, core role in development, general cellular functions, metabolism
- HIF-2 cell-specific expression, major roles in higher animal physiological adaption




Darwinian biology is at odds with rational  
reductionist drug design

But might there be drug anyway?

# So what about renal medicine?

Why does Epo production fail in diseased kidneys?

Loss of Epo production in locally injured kidney – changes in morphology and markers in interstitial fibroblasts



# Erythropoietin-producing potential in diseased kidneys?


Total inactivation of HIF prolyl hydroxylases reveals enhanced Epo-producing potential of diseased kidneys

Souma *et al.* JASN 08/06/2015

PHD1, 2, 3 triple k/o  
(Epo-Cre)





Unilateral ureteric  
obstruction model



Action of HIF prolyl hydroxylase inhibitor to increase plasma-EPO levels in healthy controls and in HD patients with and without remaining renal tissue.


**Bernhardt W M *et al.* JASN 2010;21:2151-2156**

Control (normal subjects)




Bicyclic  
isoquinolone  
inhibitor  
20mg / Kg

Nephric HD patients



Anephric HD patients



Time (hours)


## Strategy for PHI in renal anaemia?

↑ Aim to stimulate the general hypoxia response?  
+ Benefits?  
+ Risks?

↓ Aim to stimulate Epo production alone?

# HIF prolyl hydroxylase inhibitors appear safe and effective in anaemia correction in medium term (months) studies

## Randomized placebo controlled dose ranging study of GSK1278863 over 28 days *AJKD 67 861-871 (2016)*



Lower plasma Epo levels (effective dose 10-25mg od)  
Better iron balance?  
Effective in the setting of inflammation?

Define molecular mechanism at the molecular level

Define integrated physiology at the physiological level

Define clinical effects at the clinical level


Nothing (much) else will do



**With grateful thanks to:**

Martin Attwood, Tammie Bishop, Gloria Chang, Matthew Cockman, James Fielding, Norma Masson, James McAuliffe, Mike McDonough, David Mole, James Platt, Chris Pugh, Rafik Salama, Virginia Schmid, Johannes Schödel, Christopher Schofield, Peter Simpson, James Smythies, Min Sun, Ya-Min Tian, Atsu Yamamoto, Tzu-Lan Yeh


With financial support from the Wellcome Trust, the Ludwig Institute for Cancer Research, the Jeantet Foundation, CRUK, the MRC, BBSRC and the BHF



# Immune cell phenotypes following modulation of HIF prolyl hydroxylases

Single dose of prolyl hydroxylase inhibitor (FG-4497) to donor results in sustained improvement in rat kidney allograft survival

Bernhardt et al (Kai Eckardt and colleagues, Erlangen) PNAS 106 21276-21281 (2009)



Severe lymphoid dysregulation following sustained (8 week) general shPHD2 k/d

Astu Yamamoto and Chris Pugh – unpublished data

